Converting enzyme inhibitor and saralasin infusion in rats. Evidence for an additional vasodepressor property of converting enzyme inhibitor.
D000804:Angiotensin II / Q000031:analogs & derivatives*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D001920:Bradykinin / Q000494:pharmacology; D004039:Diet, Sodium-Restricted; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006977:Hypertension, Renal / Q000188:drug therapy; D008297:Male; D009392:Nephrectomy; D051381:Rats; D012083:Renin / Q000494:pharmacology; D012504:Saralasin / Q000494:pharmacology*; D014662:Vasoconstrictor Agents / Q000494:pharmacology* / Q000627:therapeutic use
D004791:Enzyme Inhibitors; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D012083:Renin; D012504:Saralasin; D001920:Bradykinin